Cortisone and QTc-Interval

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

105 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-04-01

Study Completion Date

2020-04-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Scientific and clinical data report about shortening of QTc-interval in patients treated with cortisone. Peal et al. analyzed chemical suppression of long QT syndrome (Type 2) in an in vivo zebrafish model. Their study revealed that flurandrenolide reproducibly suppressed the long QT phenotype via the glucocorticoid signaling pathway. In contrast to treatment with dexamethasone and testosterone, treatment with pure mineralocorticoid deoxycorticosterone acetate did not suppress long QT phenotype. Knockdown of the glucocorticoid receptor or, conversely, of the androgen receptor showed that flurandrenolide acting through the glucocorticoid receptor shortens ventricular action potentials. The mechanism is distinct from trafficking rescue of the defective zebrafish-ERG channel. The authors discuss that a drug normalizing repolarization would be a novel therapeutic tool in long QT syndrome and conclude that glucocorticoids could be expected to aid in the acute management of patients with long QT syndrome, e.g. in episodes of arrhythmic storm. In addition, corticoid induced normalization of the QT interval is reported in a patient with drug-induced prolongation of the QTc interval. Brostoff et al. report on a patient suffering from mucocutaneous leishmaniasis treated with sodium stibogluconate. During therapy, the QTc interval prolonged and returned to normal within 4 days after starting glucocorticoid therapy with prednisolone 20 mg twice daily.

Interrogation of the study:

* shortens cortisone the QTc-interval?
* how long is the interval until shortening of QTc-interval?
* is the effect prolonged?
* is the effect dose dependend?

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Treatment of GHD Associated With CHF

NCT03775993

Heart Failure Growth Hormone Deficiency

UNKNOWN PHASE3

Study of Gonadotropin-Releasing Hormone Pulse Frequency in Sexual Maturation and in the Menstrual Cycle

NCT00004335

Hypogonadism Precocious Puberty

COMPLETED

Growth Hormone Deficiency in Chronic Heart Failure: A Preliminary Trial

NCT00591760

Heart Failure Growth Hormone Deficiency Ischemic Heart Disease

COMPLETED PHASE2

Status of Growth Hormone/ Insulin-like Growth Factor-1 (GH/IGF-1) Axis and Growth Failure in Ataxia Telangiectasia (AT)

NCT01052623

Ataxia Telangiectasia Growth Failure

UNKNOWN PHASE4

The Risk of Adrenal Insufficiency and Cushing Syndrome Associated With Glucocorticoid Therapy in People With Chronic Inflammatory Diseases

NCT03575247

Adrenal; Insufficiency Gluccorticoid-Induced Cushing; Syndrome or Disease, Glucocorticoid-Induced

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

QTc-interval

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Neurology

Patients with inflammatory disease, especially multiple sclerosis, who underwent therapy with cortisone (\>=40mg/d)

Cortisone

Intervention Type OTHER

Observation of QTc-interval

Pulmonology

Patients after LTX (under medication possible prologing QTc-interval), who underwent therapy with cortisone (\>=40mg/d)

Cortisone

Intervention Type OTHER

Observation of QTc-interval

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cortisone

Observation of QTc-interval

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients who underwent therapy with cortisone (\>=40mg/d)

Exclusion Criteria

* patients with elevated intracranial pressure
* myocardial infarction within the last 6 months
* untreated stenosis of the coronary arteries
* right bundle branch block
* autoimmune disease

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No